Search

KSL President and CEO, Kevin Lawson, named 2021 C-Level Executives Awards Honoree

We are proud to announce that KSL's CEO, Kevin Lawson, was named as one of this year's honorees of the 2021 C-Level Executives Awards! The 2021 winners were honored on November 4, 2021 at the Statler Hotel in Buffalo, NY with a dinner and award ceremony.


Hosted by Business First and sponsored by Harter Secrest & Emery LLP, Northwest Bank and Walsh Duffield Companies, this award recognizes Western New York’s most effective business leaders for the initiative, business, and civic contributions they have made to their organizations and to the Western New York community. Including this year, 202 people have been recognized since the C-Level awards began in 2012.

KSL Chief Medical Officer, Dr. Lakshmanan Suresh, congratulates Kevin Lawson, KSL President and CEO

“This is a tremendous honor. I have to largely credit my partners, Drs. Lakshmanan Suresh and Long Shen, and our wonderful staff." Kevin said, expressing his deep appreciation of the award. "Our team is so dedicated, innovative and dynamic that I am excited to come to work every day. It is very rewarding to see our small company grow at home in Western New York.”


This year, Kevin was selected for his ability to align strategy, operations, and quality leadership. Prior to the advent of COVID-19, KSL was primarily a biomedical laboratory specializing in oncology and genomics. Thanks to Kevin's vision and enterprise, and with the help of his business partners, Dr. Long Shen and Dr. Lakshmanan Suresh, KSL was able to pivot to provide much-needed COVID testing right here in the WNY area, as well as pioneer research into the disease with community partners.


Kevin is an accomplished biotechnology executive with formidable experience identifying and building value in promising new technologies through collaborative licensing and internal basic research. Working closely with regulatory authorities at all levels — departments of health, FDA and international bodies — he has driven development, regulatory clearance, and commercialization of numerous novel reference laboratory tests and IVDs in the U.S. and around the world. He is responsible for validation and approval of many LDTs and 510k of more than 50 assays and medical devices.


Well-deserved congratulations, Kevin!